Active, not recruitingNCT04122976
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
Studying Hinman syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bayer
- Intervention
- Darolutamide(Nubeqa, BAY1841788)(drug)
- Enrollment
- 805 target
- Eligibility
- 18 years · MALE
- Timeline
- 2020 – 2026
Study locations (30)
- Urology Centers of Alabama, Homewood, Alabama, United States
- Arizona Institute of Urology, Tucson, Arizona, United States
- Genesis Comprehensive Prostate Cancer Center, San Diego, California, United States
- The Urology Center of Colorado, Denver, Colorado, United States
- Manatee Medical Research Institute, Bradenton, Florida, United States
- Advanced Urology Institute, Daytona Beach, Florida, United States
- Research by Design, LLC, Chicago, Illinois, United States
- First Urology, PSC, Jeffersonville, Indiana, United States
- Wichita Urology Group, Wichita, Kansas, United States
- Southcoast Centers for Cancer Care, Fairhaven, Massachusetts, United States
- New Jersey Urology, Englewood, New Jersey, United States
- Beacon Cancer Care, Beacon, New York, United States
- Integrated Medical Professionals, PLLC, North New Hyde Park, New York, United States
- Premier Medical Group of the Hudson Valley, PC, Poughkeepsie, New York, United States
- Associated Medical Professional Urology, Syracuse, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04122976 on ClinicalTrials.govOther trials for Hinman syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07307274A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight AdultsSyntis Bio
- ACTIVE NOT RECRUITINGPHASE2NCT07281937A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesVerdiva Bio Dev Limited
- ENROLLING BY INVITATIONNANCT07283107Trial to Evaluate the Impact of Various Behavioural Interventions to Increase Mammography Uptake Among Singaporean WomenNational University Hospital, Singapore
- RECRUITINGNANCT07268508Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory FunctionHospices Civils de Lyon
- RECRUITINGPHASE2NCT06927739Focused Orticumab Research for Treating Inflammation in Coronary ArteriesAbcentra
- RECRUITINGNANCT07054333Objective Measurement of Pain Regulation in Individuals Who Have Received Internet-delivered Exposure-based Cognitive Behavior TherapyKarolinska Institutet
- RECRUITINGPHASE4NCT07030517A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple MyelomaJohnson & Johnson Private Limited
- RECRUITINGPHASE2NCT06846320Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety DisorderAbbVie